A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom

NCT ID: NCT01292213

Last Updated: 2014-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the role of Haemophilus influenzae and other bacteria in causing chronic cough, through a direct comparison of chronic cough cases and healthy controls recruited from paediatric respiratory clinics in the United Kingdom.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infections, Respiratory Tract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.

Cough swab

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Oropharyngeal swab

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Nasopharyngeal swabs

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.

Blood sample

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.

Bronchoscopy/ bronchoalveolar lavage samples

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.

Data collection

Intervention Type OTHER

Questionnaire completion.

Controls

Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.

Cough swab

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Oropharyngeal swab

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Nasopharyngeal swabs

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.

Blood sample

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.

Bronchoscopy/ bronchoalveolar lavage samples

Intervention Type PROCEDURE

Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.

Data collection

Intervention Type OTHER

Questionnaire completion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cough swab

Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Intervention Type PROCEDURE

Oropharyngeal swab

Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.

Intervention Type PROCEDURE

Nasopharyngeal swabs

Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.

Intervention Type PROCEDURE

Blood sample

Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.

Intervention Type PROCEDURE

Bronchoscopy/ bronchoalveolar lavage samples

Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.

Intervention Type PROCEDURE

Data collection

Questionnaire completion.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who the investigator believes that parent(s)/ legally acceptable representative can and will comply with the requirements of the protocol.
* A male or female child between, and including, six to 72 months of age at the time of enrolment.
* Written informed consent obtained from the parent(s)/ legally acceptable representative of the subject.
* No antibiotic therapy within four weeks prior to the visit.
* No cystic fibrosis or known major immunodeficiency such as agammaglobulinaemia, T cell deficiency or Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome.
* No documented evidence or suspicion of gastroesophageal reflux disease.
* No evidence of an upper viral respiratory infection four weeks prior to the visit.

In addition, all subjects regarded as 'cases' must satisfy all the following criteria at study entry:

* Persistent cough greater than eight weeks.
* No response to five-day prednisolone treatment.
* Chest X-ray showing no evidence of a lobar pneumonia or gross structural abnormality.

In addition, all subjects regarded as 'controls' must satisfy the following criteria at study entry:

* No respiratory symptoms four weeks prior to the visit.
* No documented evidence or suspicion of lung disease upon physical examination.

Exclusion Criteria

* Concurrently participating in another study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
* Use of any investigational or non-registered product within 30 days prior to study procedures, or planned use during the study period.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
* Child in care.
Minimum Eligible Age

6 Months

Maximum Eligible Age

72 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Belfast, , United Kingdom

Site Status

GSK Investigational Site

Bristol, , United Kingdom

Site Status

GSK Investigational Site

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

112956

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.